Menu
  • Home
  • London Exchange
  • Euronext
  • Australian Exchange
  • Wire
  • Contact Us
  • Business & Finance
NewsnReleases

Interferon treatment trial appears to be a major breakthrough against COVID-19

Posted on July 25, 2020
Interferon treatment trial appears to be a major breakthrough against COVID-19 1
The study reported “very significant” reductions in breathlessness among patients who received the treatment and highlighted how patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, according to the study claims.

TORONTO: The preliminary results of a clinical trial by a UK biotech suggests that an interferon inhalation treatment for COVID-19 reduces the number of patients needing intensive care.

In the UK study, the treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus. The initial findings suggest the treatment cut the odds of a COVID-19 patient in hospital developing severe disease – such as requiring ventilation – by 79%.

The study reported “very significant” reductions in breathlessness among patients who received the treatment and highlighted how patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, according to the study claims.

In addition, the average time patients spent in hospital is said to have been reduced by a third, for those receiving the new drug – down from an average of nine days to six days.

The treatment in the study used interferon beta, as opposed to the patent-pending interferon alpha 2b (IFN-a2b) treatment developed by BetterLife called AP-003.

Whether alpha or beta, both interferon proteins are produced when the body encounters a viral infection and act as antiviral agents, modulating functions of the immune system.  Interferons were so named for their ability to “interfere” with viral replication by protecting cells from virus infections.

IFN-a2b has been used with great success with other respiratory illnesses. Interferon treatments have been studied against coronaviruses including MERS-CoV, SARS-Cov-1 and now SARS-CoV-2 (the causative agent of COVID-19).

Of the three coronaviruses which cause severe human disease, SARS-CoV-2 displays substantial sensitivity to interferon alpha. Studies in COVID-19 patients show that IFN-a2b inhalation reduces the infection rate of SARS-CoV-2.

BetterLife is planning to initiate its Phase II study later this summer with its proprietary IFN-a2b formula called AP-003.  AP-003 is a patent pending isoform-free form of interferon alpha 2b. This means that as a purer form of interferon it is potentially less toxic, clearing the way for higher doses to be administered.

BetterLife hope that an inhaler, similar to one used in the UK study, will deliver AP-003 directly to a patient’s lungs in the hope of stimulating immune response. The treatment is aimed at preventing infected patients deteriorating from requiring oxygen to being placed on a ventilator, as suggested by the findings of the UK study.

The company is also aiming to develop a low dose version of AP-003 that may serve as a prophylaxis or prevention treatment for front-line workers and those at high risk for COVID-19 infections.

In discussing the news, Ahmad Doroudian, Chief Executive Officer of BetterLife commented “We are encouraged by the positive results from this trial as it further confirms the proof of concept of anti-COVID treatment via IFN inhalation. We look forward to our proposed 150 patient clinical trials using AP-003 (inhaled IFN alpha 2b) in COVID-19 patients.

BetterLife’s team believes that the isoform-free IFN alpha2b will provide a potentially superior treatment regimen for Covid-19 patients, as IFN-a2b has already been used to successfully treat other viral infections such as HCV and HBV.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Track all markets on TradingView

Investing.comThe Exchange Rates are powered by Investing.com.

Site Navigation

  • Home
  • Listed Companies
  • Contact Us
  • London Stock Exchange
  • Singapore Exchange
  • Canadian Exchange
  • Australian Exchange
  • Oslo Bourse
  • PSX
  • Ratings
  • Euronext
  • MENA
  • Nasdaq Nordic
  • Wire
  • Business & Finance
  • Gadget Reviews
  • About Us: A Comprehensive Financial News Database

All news and articles on NewsnReleases are based on press releases, corporate announcements and analysts’ reports issued to London Stock Exchange (LSE), Euronext, Singapore Exchange (SGX), Japan Stock Exchange (JPX), Dubai Financial Market (DFM), Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange etc.

Listed Companies

Equity Markets and Stock Exchanges

NNR
©2025 NewsnReleases | WordPress Theme by Superb WordPress Themes